MedTrace Logo

Preoperative Supra-inguinal Fascia Iliaca Block for Positioning Analgesia in Hip Fracture Patients Undergoing Spinal Anesthesia

NCT07556614 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2026-04-29

No results posted yet for this study

Summary

The goal of the clinical trial is to learn if preoperative Superficial Inguinal Fascia Iliaca (SIFI) block works to reduce pain during positioning for spinal anesthesia. Investigators will compare this block to no block to see if it works to reduce procedural pain. All participants will be divided into two groups. Group A will be given preoperative SIFI block prior to spinal anesthesia positioning, while Group B patients will receive no block. They will be assessed by the Visual Analogue Scale (VAS) at rest, during positioning, and at 12 and 24 hours postoperatively. Efficacy will be measured by using the VAS pain scoring system. The final assessment will be done at the 24-hour follow-up. A total of 132 patients (66 per group) fulfilling the inclusion criteria are enrolled in the study.

Conditions

  • Hip Fractures
  • Supra-inguinal Fascia Iliaca Block
  • Spinal Anesthesia

Interventions

DRUG

Isobaric bupivacaine 0.5%

Patients in the intervention group (A) will receive a preoperative supra-inguinal fascia Iliaca block. Under aseptic conditions, a high-frequency linear ultrasound probe (8-12 MHz) will be positioned at the anterior superior iliac spine (ASIS) and directed medially in an hourglass pattern. A short-beveled Sonoplex needle will be inserted in-plane through the sartorius muscle towards the fascia iliaca. Following hydro-dissection with 4-5 mL of normal saline to confirm the correct needle placement, 30 mL of 0.25% bupivacaine will be administered. Appropriate spread will be confirmed by the separation of the fascia iliaca from the iliacus muscle, and sensory coverage over the lateral, medial, and anterior thigh will be checked with cold saline. Spinal anesthesia will be performed using a 25-gauge. Quinke spinal needle at the L2-L4 level, with 1.5-2 mL of 0.5% isobaric bupivacaine. After the procedure, patients will be repositioned supine, and surgery will proceed.

Sponsors & Collaborators

  • Ghurki Trust and Teaching Hospital

    lead OTHER

Principal Investigators

  • Dr. Namra Nadeem · Ghurki Trust Teaching Hospital

  • Prof. Dr. Leena Ayub · Ghurki Trust Teaching Hospital

  • Dr. Shahid Dar · Ghurki Trust Teaching Hospital

  • Dr. Umer Farooq · Ghurki Trust Teaching Hospital

  • Dr. Adeel Shahid · Ghurki Trust Teaching Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2025-11-15
Completion
2025-11-20

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07556614 on ClinicalTrials.gov